These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28277814)

  • 21. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
    Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
    Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive values of anti-müllerian hormone, antral follicle count and ovarian response prediction index (ORPI) for assisted reproductive technology outcomes.
    Ashrafi M; Hemat M; Arabipoor A; Salman Yazdi R; Bahman-Abadi A; Cheraghi R
    J Obstet Gynaecol; 2017 Jan; 37(1):82-88. PubMed ID: 27976974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AFC vs. AMH: prediction of ovarian response in women with endometrioma undergoing controlled ovarian stimulation.
    Ersahin AA; Arpaci H; Ersahin SS; Celik N; Acet M
    Eur Rev Med Pharmacol Sci; 2017 May; 21(10):2499-2503. PubMed ID: 28617534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Müllerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Jun; 69(3):225-232. PubMed ID: 27352270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
    Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
    Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Low circulating anti-Müllerian hormone and normal follicle stimulating hormone levels: which prognosis in an IVF program?].
    Grzegorczyk-Martin V; Khrouf M; Bringer-Deutsch S; Mayenga JM; Kulski O; Cohen-Bacrie P; Benaim JL; Belaisch-Allart J
    Gynecol Obstet Fertil; 2012; 40(7-8):411-8. PubMed ID: 22521986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone.
    Nielsen AP; Korsholm AS; Lemmen JG; Sylvest R; Sopa N; Nyboe Andersen A
    Gynecol Endocrinol; 2016 Aug; 32(8):625-628. PubMed ID: 26891977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of AMH on IVF success.
    Gomez R; Schorsch M; Hahn T; Henke A; Hoffmann I; Seufert R; Skala C
    Arch Gynecol Obstet; 2016 Mar; 293(3):667-73. PubMed ID: 26449238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of anti-Mullerian hormone for pregnancy outcomes following assisted reproductive techniques (ART) in Southwest China.
    Liu L; Sun XY; Yang H; Feng XJ; Lan YZ
    Reprod Health; 2022 Dec; 19(1):224. PubMed ID: 36514055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational study.
    Li R; Gong F; Zhu Y; Fang W; Yang J; Liu J; Hu L; Yang D; Liang X; Qiao J
    Reprod Biomed Online; 2016 Oct; 33(4):506-512. PubMed ID: 27502068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is anti-Müllerian hormone associated with IVF outcomes in young patients with diminished ovarian reserve?
    Pereira N; Setton R; Petrini AC; Lekovich JP; Elias RT; Spandorfer SD
    Womens Health (Lond); 2016; 12(2):185-92. PubMed ID: 26901454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve.
    Lekamge DN; Lane M; Gilchrist RB; Tremellen KP
    J Assist Reprod Genet; 2008; 25(11-12):515-21. PubMed ID: 18972201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice.
    La Marca A; Sunkara SK
    Hum Reprod Update; 2014; 20(1):124-40. PubMed ID: 24077980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes.
    Styer AK; Gaskins AJ; Brady PC; Sluss PM; Chavarro JE; Hauser RB; Toth TL
    Fertil Steril; 2015 Nov; 104(5):1153-61.e1-7. PubMed ID: 26315051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos.
    Majumder K; Gelbaya TA; Laing I; Nardo LG
    Eur J Obstet Gynecol Reprod Biol; 2010 Jun; 150(2):166-70. PubMed ID: 20223579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Follicular phase endocrine characteristics during ovarian stimulation and GnRH antagonist cotreatment for IVF: RCT comparing recFSH initiated on cycle day 2 or 5.
    Blockeel C; Sterrenburg MD; Broekmans FJ; Eijkemans MJ; Smitz J; Devroey P; Fauser BC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1122-8. PubMed ID: 21307142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles.
    La Marca A; Papaleo E; Grisendi V; Argento C; Giulini S; Volpe A
    BJOG; 2012 Sep; 119(10):1171-9. PubMed ID: 22805536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The significance of serum anti-Müllerian hormone (AMH) levels in patients over age 40 in first IVF treatment.
    Tokura Y; Yoshino O; Ogura-Nose S; Motoyama H; Harada M; Osuga Y; Shimizu Y; Ohara M; Yorimitsu T; Nishii O; Kozuma S; Kawamura T
    J Assist Reprod Genet; 2013 Jun; 30(6):821-5. PubMed ID: 23640374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing four ovarian reserve markers--associations with ovarian response and live births after assisted reproduction.
    Brodin T; Hadziosmanovic N; Berglund L; Olovsson M; Holte J
    Acta Obstet Gynecol Scand; 2015 Oct; 94(10):1056-63. PubMed ID: 26184379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.